[Clinical experience with ceftizoxime suppositories in pediatrics]

Area of Science:

• Pediatric infectious diseases
• Pharmacology
• Antimicrobial therapy

Background:

• Alternative drug delivery methods are crucial for pediatric patients unable to tolerate standard oral or injectable medications.
• Ceftizoxime, a third-generation cephalosporin, has demonstrated broad-spectrum antibacterial activity.

Observation:

• Six pediatric patients with acute bronchopneumonia or acute pharyngobronchitis received ceftizoxime suppositories (CZX-S) at 125 mg or 250 mg doses.
• Patients were selected due to contraindications or intolerance to conventional ceftizoxime formulations.

Findings:

• All patients exhibited a "good" clinical response to CZX-S treatment.
• Causative organisms, including Haemophilus influenzae and Staphylococcus aureus, were eradicated in two patients.
• Minor adverse events included one case of diarrhea and one instance of transiently elevated GPT levels.

Implications:

• Ceftizoxime suppositories represent a viable and effective therapeutic option for pediatric bacterial infections.
• This formulation expands treatment accessibility for children who cannot receive standard ceftizoxime administration routes.
• Further research into suppository formulations for pediatric antimicrobials is warranted.